Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF).

MLA

Cho, Sungji, et al. “Cardioprotection by the Adiponectin Receptor Agonist ALY688 in a Preclinical Mouse Model of Heart Failure with Reduced Ejection Fraction (HFrEF).” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 171, Feb. 2024, p. 116119. EBSCOhost, https://doi.org/10.1016/j.biopha.2023.116119.

APA

Cho, S., Dadson, K., Sung, H. K., Ayansola, O., Mirzaesmaeili, A., Noskovicova, N., Zhao, Y., Cheung, K., Radisic, M., Hinz, B., Sater, A. A. A., Hsu, H. H., Lopaschuk, G. D., & Sweeney, G. (2024). Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF). Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 171, 116119. https://doi.org/10.1016/j.biopha.2023.116119

Chicago

Cho, Sungji, Keith Dadson, Hye Kyoung Sung, Oyeronke Ayansola, Ali Mirzaesmaeili, Nina Noskovicova, Yimu Zhao, et al. 2024. “Cardioprotection by the Adiponectin Receptor Agonist ALY688 in a Preclinical Mouse Model of Heart Failure with Reduced Ejection Fraction (HFrEF).” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 171 (February): 116119. doi:10.1016/j.biopha.2023.116119.